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Available online 26 October 2016Fibroblasts from a male patient with compound heterozygous variants in the tyrosine hydroxylase gene (TH;
OMIM: 191290; c.[385-CNT]; [692-GNC]/p.[R129*]; [R231P]), the rate-limiting enzyme for dopamine synthesis,
were reprogrammed to iPSCs using episomal reprogramming delivering the reprogramming factorsOct3/4, Sox2,
L-Myc, Lin28, Klf4 and p53 shRNA Okita et al. (2011). Pluripotency of TH-1 iPSC was veriﬁed by immunohisto-
chemistry and RT-PCR analysis. Cells exhibited a normal karyotype and differentiated spontaneously into the 3
germ layers in vitro. TH-1 iPSC represents the ﬁrst model system to study the pathomechanism of this rare met-
abolic disease and provides a useful tool for drug testing.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).(
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Fibroblasts from a male patient with compound heterozygous vari-
ants in the tyrosine hydroxylase gene (TH, DYT14; OMIM: 191290;
HGNC: 11782; c.[385-CNT]; [692-GNC]/p.[R129*]; [R231P]) were epi-
somally reprogrammed using the reprogramming factors Oct3/4, Sox2,
L-Myc, Klf4, Lin28 and an shRNA directed against p53 according to
Okita et al. (2011). Karyotype was determined by ﬂuorescence R-
banding and provided a normal diploid 46,XY karyotype (Fig. 1A). Ab-
sence of episomal plasmids was analysed by RT-PCR using EBNA-and
plasmid-speciﬁc primers (Fig. 1B; Table 1). Presence of the pathogenic
variants was veriﬁed by PCR followed by Sanger Sequencing (Fig. 1C,
Table 1). Expression of pluripotencymarkers was detected by immuno-
ﬂuorescence staining speciﬁc for Oct3/4, Sox2, Nanog, Lin28 and SSEA-4
(Fig. 1D) aswell as by RT-PCRusing gene-speciﬁc primers (Fig. 1E; Table
1). Differentiation potential was tested using embryoid body (EB)
formation followed by RT-PCR (Haase et al., 2009) amplifying AFP (en-
doderm), MLC2A (mesoderm) and βIII-tubulin (ectoderm; Fig. 1F) and
immunoﬂuorescence staining for endodermal (AFP), mesodermal
(SMA) and ectodermal (βIII-tubulin) markers (Fig. 1G).://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. TH-1 iPSCs exhibit a normal karyotype (46,XY; A). No expression from the episomal plasmids used for reprogramming was detectable with RT-PCR neither in the untransfected
ﬁbroblasts of the patient (Fib) nor in the TH-1 iPSCs (iPSC; B). Plasmid pCXLE-hOCT3/4-shp53-F (P) was used as positive control for the ampliﬁcation of the EBNA site (B). Presence of
both single nucleotide exchanges described for the patient was veriﬁed by PCR ampliﬁcation and subsequent Sanger Sequencing (C). TH-1 iPSCs show expression of pluripotency
marker genes in the immunoﬂuorescence staining (D) as well as on RNA level as detected by RT-PCR (E). TH-1 iPSCs can be differentiated into all three germ layers using EB formation
as shown by immunoﬂuorescence staining (F) and RT-PCR (G). Abbreviations:+: cDNA synthesis performed with reverse transcriptase;−: cDNA synthesis performed without reverse
transcriptase; P: plasmid pCXLE-hOCT3/4-shp53-F; co: control iPSC line; NC: NCCIT cells used as positive control. Scale bars represent 100 μm.
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Table 1
Primers used in the study.
Gene
symbol Sequence (fwd and rvs; 5′–3′)
Product
size (bp)
Annealing
temperature (°C)
β-actin CATGGAGAAAATCTGGCACCAC 409 56
GCACAGCTTCTCCTTAATGTCAC
Oct3/4 GAACCAGTATCGAGAACCG 383 56
TCAGTTTGAATGCATGGGAG
Sox2 CACATGTCCCAGCACTACCAG 77 56
CACATGTGTGAGAGGGGCAG
Nanog AAACAGAAGACCAGAACTGTG 191 56
CAGTTGTTTTTCTGCCACCTCT
Lin28 CCATATGGTAGCCTCATGTC 126 56
CAATTCTGTGCCTCCGGG
βIII tubulin CAACAGCACGGCCATCCAGG 242 66
CTTGGGGCCCTGGGCCTCCGA
AFP ACTCCAGTAAACCCTGGTGTTG 255 55
GAAATCTGCAATGACAGCCTCA
MLC2A GAGGAGAATGGCCAGCAGGAA 446 60
GCGAACATCTGCTCCACCTCA
EBNA GGATCACTAGGTGATATCGAGC 61 58
ACCAGACAAGAGTTTAAGAGATATGTATC
Oct4 CATTCAAACTGAGGTAAGGG 124 60
(exogen) TAGCGTAAAAGGAGCAACATAG
L-Myc GGCTGAGAAGAGGATGGCTAC 122 60
(exogen) TTTGTTTGACAGGAGCGACAAT
Lin28 AGCCATATGGTAGCCTCATGTCCGC 251 60
(exogen) TAGCGTAAAAGGAGCAACATAG
TH CCGCGGTTCATTGGGCG 230 56
Exon 3 CACCAGCTCACCTCAAACAC
TH GGCTTCTCGGACCAGG 170 57
Exon 6 GACAAGATGGGTCCTCC
Table 2
Antibodies used for immunoﬂuorescence staining.
Application Antibody Dilution Company Cat. #
Mouse anti-Oct4 1:100 Santa Cruz sc-5279
Mouse anti-Sox2 1:100 Merck Millipore MAB4343
Pluripotency Mouse anti-Nanog 1:100 Thermo Fisher
Scientiﬁc
MA1-017
Mouse anti-SSEA4 1:100 Santa Cruz sc-21,704
Mouse anti-AFP 1:100 Abcam ab3980
Differentiation Rabbit anti-SMA 1:100 Abcam ab5694
Mouse anti-βIII-Tubulin 1:100 Abcam ab78078
Secondary
antibodies
Alexa Fluor goat anti
mouse 488
1:500 Thermo Fisher
Scientiﬁc
A-10667
Goat anti-Rabbit IgG
(H + L), TRITC conjugate
1:500 Thermo Fisher
Scientiﬁc
A16101
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3.1. iPSC reprogramming
Fibroblasts were isolated and cultured in DMEM supplemented
with 10% FBS, 1% Penicillin/Streptomycin, 0.1 mM non-essential
amino acids and 50 μM β-mercaptoethanol (Invitrogen). Cells
were reprogrammed in passage 13 by electroporation using the 4D-
Nucleofector System (Lonza) and plasmids pCXLE-hOCT3/4-shp53-F,
pCXLE-hUL and pCXLE-hSK Okita et al. (2011). After electroporation,
cells were kept in ﬁbroblast medium for three days, then for the
rest of the reprogramming in ESC medium consisting of KnockOut
DMEM (Gibco) supplemented with 20% KnockOut SerumReplacement,
1% non-essential amino acids (Gibco), 1 mM L-Glutamine (Gibco),
0.1 mM β-mercaptoethanol (Gibco), 4 ng/ml human recombinant
bFGF (R&D Systems). Medium was changed daily until iPSC colonies
formed. After manual picking, iPSC lines were maintained on Matrigel
(Corning) coated plates in mTeSR1 medium (Stem Cell Technologies).
3.2. RT-PCR analysis
RNAwas extracted using Trizol® (Invitrogen), 1 μg RNAwasdigested
with DNAseI (Invitrogen) according to the manufacturer's instructions
and cDNA was synthesized from 0.5 μg DNAseI digested RNA using
SuperScript® III Reverse Transcriptase and Oligo(dT)20 primer (both
Invitrogen) according to the manufacturer's protocol. PCR reactions
were performed using Crimson Taq Polymerase (New England Biolabs)
using standard PCR conditions (95 °C 30 s (1×); 95 °C 30 s, 55–66 °C
1 min, 68 °C 1 min (35×); 68 °C 5 min (1×), 12 °C (hold); for
details see Table 1). PCR products were subjected to agarose gel
electrophoresis.
3.3. In vitro differentiation via embryoid body formation
iPSCs were harvested using ReLeSR (Stem Cell Technologies),
singled, counted and 9 × 105 cells per well were transferred to an
AggreWell 800™ plate (Stem Cell Technologies) containing ESCmedium without bFGF but supplemented with 10 μM ROCK inhibitor
(Y-27632; SIGMA) to form uniform embryoid bodies (EBs) overnight.
The following day, EBs were transferred to Ultra low attachment plates
(Greiner) and cultivated for 6 days in ESC medium without bFGF. On
day 8, EBs were dissociated with Trypsin (Invitrogen) and plated onto
gelatin coated plates (with cover slips for immunoﬂuorescence staining,
without for RNA isolation and RT-PCR). Mediumwas switched to differ-
entiation medium (ESC medium without bFGF/MEF medium 1:1 (v/v))
and cells were cultivated for 7 more days. Cells were ﬁxed on day 15 of
differentiation with 4% paraformaldehyde (PFA) in PBS for immunoﬂu-
orescence staining or lysed with Trizol® for RNA isolation and RT-PCR.3.4. Immunoﬂuorescence staining
Presence of speciﬁc pluripotency marker genes (Oct3/4, Sox2,
Nanog, SSEA-4) or germ layer markers (AFP, βIII-Tubulin, SMA) was
analysed using immunoﬂuorescence staining. For detection of
pluripotency markers, iPSCs were seeded onto gelatine-coated cover
slips in Essential 8™ Flex medium (Gibco) and cultivated for 4 days be-
fore ﬁxation. iPSCs or differentiated cells after EB formation were ﬁxed
with 4% PFA/PBS (15 min, room temperature (RT)), permeabilized
with 1% Triton X-100/PBS for 10 min at RT and blocked with 5% BSA/
0.1% Triton X-100/PBS for 1 h at RT. Cells were incubated with the pri-
mary antibodies (Table 2) in 5% BSA/PBS for 1 h at RT, followed by incu-
bation in 5% BSA/PBSwith the secondary antibodies (Table 2) for 30min
at RT. Nuclei were stained with DAPI included in themountingmedium
(Fluoromount-G with DAPI, eBioscience). Cells were analysed using a
ﬂuorescent microscope (Leica) using Leica Imaging Software.3.5. Karyotyping
After trypsinisation, metaphases were prepared according to
standard procedures. Fluorescence R-banding using chromomycin A3
and methyl green was performed as described in detail earlier
(Schlegelberger et al., 1999). A minimum of 20 metaphase spreads
were analysed and the chromosomes were classiﬁed according to the
International System for Human Cytogenetic Nomenclature (ISCN
2013).3.6. DNA isolation and Sanger sequencing
To conﬁrm the presence of the pathogenic deletion in the TH gene,
primers were designed to amplify the region of interest. iPSCs were
lysed using DNAzol® (MRC Inc.) and DNA was extracted according to
the manufacturer's instructions. 100 ng DNA was used for PCR using
Crimson Taq Polymerase and standard PCR conditions (Table 1). PCR
products were cloned into pGEM®-TEasy (Promega) and 10 clones for
each mutation where sequenced by GATC Biotech (Köln, Germany).
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